Xerostomia is a subjective feeling, caused by different reasons, many of the systemic many diseases are complications, some are the result of inevitable development. The side effect of the medicine is also one of the important factors that cause dry mouth. Xerostomia is a condition caused by a lack of saliva in the mouth. The amount of saliva in the mouth depends on the balance between production and consumption. If the amount of saliva produced is less than the amount consumed, there is a negative balance, indicating dry mouth.
This report contains market size and forecasts of Xerostomia (Dry Mouth Disease) Therapeutics in Global, including the following market information:
Global Xerostomia (Dry Mouth Disease) Therapeutics Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Xerostomia (Dry Mouth Disease) Therapeutics market was valued at 570.2 million in 2021 and is projected to reach US$ 668.4 million by 2028, at a CAGR of 2.3% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Artificial Saliva Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Xerostomia (Dry Mouth Disease) Therapeutics include Acacia Pharma, Church & Dwight, GlaxoSmithKline, Hikma Pharmaceuticals, Lupin, OraCoat, Parnell Pharmaceuticals, Pendopharm and Pfizer, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Xerostomia (Dry Mouth Disease) Therapeutics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Xerostomia (Dry Mouth Disease) Therapeutics Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Xerostomia (Dry Mouth Disease) Therapeutics Market Segment Percentages, by Type, 2021 (%)
Artificial Saliva
Salivary Stimulants
Saliva Substitutes
Drugs
Salivary Pens
Others
Global Xerostomia (Dry Mouth Disease) Therapeutics Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Xerostomia (Dry Mouth Disease) Therapeutics Market Segment Percentages, by Application, 2021 (%)
Retail Pharmacies
Hospital Pharmacies
Online Pharmacies
Global Xerostomia (Dry Mouth Disease) Therapeutics Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Xerostomia (Dry Mouth Disease) Therapeutics Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Xerostomia (Dry Mouth Disease) Therapeutics revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Xerostomia (Dry Mouth Disease) Therapeutics revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Acacia Pharma
Church & Dwight
GlaxoSmithKline
Hikma Pharmaceuticals
Lupin
OraCoat
Parnell Pharmaceuticals
Pendopharm
Pfizer
Sun Pharmaceutical Industries
Synedgen